Opinion

Gilberto Lopes: My top ASCO24 lung cancer abstracts!

Photo of Gilberto Lopes taken from med.miami.edu

May 27, 2024, 04:19

Gilberto Lopes: My top ASCO24 lung cancer abstracts!

Gilberto Lopes, Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared a post on X:

“My top ASCO24 LCSM abstracts!
(Nine, not ten, because it’s Saturday)

Top 10 Lung

Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study. LBA4
Durvalumab +/- tremelimumab as consolidation therapy for patients with limited-stage small-cell lung cancer (LS-SCLC): Results from the phase 3 ADRIATIC study.
KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. LBA8509
Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.
Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.
Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial. LBA 8505
Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial. Abstract 8508
Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study. 8504
Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.”

Source: Gilberto Lopes/X
.

abstracts Adagrasib ADRIATIC study Amivantamab ASCO 2024 ASCO 24 ASCO24 cancer chemotherapy crizotinib CROWN study docetaxel Durvalumab EGFR-mutant EVOKE-01 study Gilberto Lopes HARMONi-A trial ivonescimab KRASG12C mutation KRYSTAL-12 LAURA study lazertinib LCSM lorlatinib MARIPOSA study non small cell lung cancer non-squamous OncoDaily Oncology osimertinib Palliative Care PALOMA-3 trial Sacituzumab govitecan telehealth Tremelimumab

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage